TQB2618 + penpulimab + paclitaxel + cisplatin

TQB2618 + penpulimab + paclitaxel + cisplatin is an investigational four-drug combination regimen evaluated in first-line treatment and relapsed/metastatic head and neck squamous cell carcinoma and recurrent/metastatic nasopharyngeal carcinoma. - TQB2618 is a monoclonal antibody targeting TIM-3 (T cell immunoglobulin and mucin domain-3), functioning as a checkpoint inhibitor to enhance anti-tumor immune responses. - Penpulimab is a monoclonal antibody targeting PD-1 (programmed cell death protein 1), functioning as a checkpoint inhibitor to block PD-1/PD-L1 interaction, augmenting T-cell mediated immune response. - Paclitaxel is a small molecule cytotoxic agent that stabilizes microtubules, disrupting mitosis and inducing cancer cell apoptosis. - Cisplatin is a small molecule platinum-based cytotoxic agent that causes DNA crosslinking and apoptosis in rapidly dividing cells. The primary indication is metastatic/recurrent head and neck squamous cell carcinoma and nasopharyngeal carcinoma, generally in a first-line or post-platinum, post-checkpoint inhibitor setting[1][4][7].